JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Construction of ROS-responsive cascade-targeted liposomes and investigation of their anti-AD effects

  • 0School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, People's Republic of China.
International Immunopharmacology +

|

July 20, 2025

|

July 20, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed novel liposomes that target Alzheimer's disease pathology. These liposomes enhance drug delivery to the brain, reducing oxidative stress and neuroinflammation for improved Alzheimer's treatment.

Area Of Science

  • Neuroscience
  • Biomedical Engineering
  • Pharmacology

Background

  • Oxidative stress and neuroinflammation are key drivers in Alzheimer's disease (AD) pathogenesis, linked to beta-amyloid production.
  • Current AD treatments face challenges due to poor drug water solubility and limited blood-brain barrier (BBB) penetration.

Purpose Of The Study

  • To develop a drug delivery system that overcomes BBB limitations and targets neuroinflammation in Alzheimer's disease.
  • To enhance the therapeutic efficacy of resveratrol (Res) for Alzheimer's disease treatment.

Main Methods

  • Constructed reactive oxygen species (ROS)-responsive cascade-targeting liposomes (ROS@Res-Lip) using DSPE-PEG2000-MG1 and DSPE-TK-PEG2000-Bor.
  • Incorporated ROS-responsive thioketal (TK) bonds and borneol (Bor) to reduce ROS and enhance BBB penetration.
  • Utilized MG1 peptide for targeted delivery of resveratrol to M1-type microglia.

Main Results

  • Significantly increased drug concentration within the brain.
  • Demonstrated enhanced therapeutic efficacy for Alzheimer's disease treatment.
  • Achieved anti-inflammatory, antioxidant, and neuroprotective effects.

Conclusions

  • ROS@Res-Lip effectively targets M1-type microglia and promotes their conversion to M2-type microglia.
  • The developed liposomes show potential for improved Alzheimer's disease therapy by addressing oxidative stress and neuroinflammation.
  • This targeted drug delivery approach offers a promising strategy for overcoming BBB challenges in AD treatment.

Keywords: